2018 Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) Drug Analysis - ResearchAndMarkets.com

DUBLIN--()--The "Drug analysis: Opdivo" drug pipelines has been added to ResearchAndMarkets.com's offering.

Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T cells.

PD-1 and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and B7 family. The B7 family cell surface molecules and the cytotoxic T-lymphocyte antigen 4 family both regulate complex signaling pathways that affect T-cell activation, tolerance, and immunopathology.

Blocking the interactions between PD-1 and its corresponding ligands prevents T-cell exhaustion in patients with cancer, allowing the T cells to combat the tumor via natural immune response mechanisms.

Product Profiles

  • Opdivo: Colorectal cancer (CRC)
  • Opdivo: Head and neck cancer
  • Opdivo: Hepatocellular carcinoma (HCC)
  • Opdivo: Bladder cancer
  • Opdivo: Glioblastoma (GBM)
  • Opdivo: Renal cell cancer (RCC)
  • Opdivo: Non-small cell lung cancer (NSCLC)
  • Opdivo: Gastric cancer
  • Opdivo: Melanoma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/sx5njt/2018_opdivo?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs